Yahoo! News: Electricity cap used to treat brain tumors
The University of Cincinnati is one of the trial sites for the TRIDENT clinical trial, testing the effectiveness of electrical field treatment for glioblastoma patients earlier in treatment regimens.
Kyle Wang, MD, a University of Cincinnati Cancer Center member and assistant professor of clinical radiation oncology in the UC College of Medicine, explained that human cells naturally use electricity to line up certain cellular structures, including materials called mitotic spindles, that are used for cell division and growth. To prevent tumor cells from growing, an alternating electric field can be focused at the tumor to disrupt this process.
The treatment is delivered through a group of electrical arrays, a configuration of electrodes that looks like a mesh cap worn on the head, called an Optune device.
A number of local TV stations across the country, as well as Yahoo! News, have featured the research in recent segments.
Watch the Yahoo! News segment, originally aired on NewsChannel 5 Nashville.
Featured photo at top of patient Siyun Huang, right, wearing an Optune device while talking with University of Cincinnati clinical research professional Alexis Brenner, left. Photo/Leigh Vukov/UC Health.
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
An expert pieced together this Roman document like a puzzle
September 1, 2026
National media highlighted a new project by UC Classics Assistant Professor Matthijs Wibier to piece together and translate an ancient Roman text from fragments buried in the desert for more than 1,600 years.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.